距骨骨软骨损伤的诊断及关节镜治疗分析

目的 探讨距骨骨软骨损伤的诊断方法及使用关节镜治疗的临床效果.方法 选取36例距骨骨软骨损伤的患者,均采取踝关节镜手术治疗,观察其治疗效果.结果 36例距骨骨软骨损伤患者的优良率为88.9%,治疗前后踝关节功能及症状比较差异有统计学意义（P ＜0.05）.治疗前后中度疼痛以上比例比较差异有统计学意义（P ＜0.05）.结论 负重疼痛是距骨骨软骨损伤的主要症状,及时发现、及早治疗是治愈的关键.采用关节镜治疗效果显著、微创、安全可靠,值得在临床上合理推广.     

踝关节骨折并距骨骨软骨损伤的关节镜治疗

目的 探讨关节镜技术在踝关节骨折并距骨骨软骨损伤治疗中的应用及效果.方法 对23例踝关节骨折合并距骨骨软骨损伤的患者,在切开复位骨折内固定的同时行关节镜下取出软骨碎片、关节面修整及钻孔.结果 本组随访6～25个月,平均13.5个月.笔者按Must和Teipner评分标准:优18例,良3例,可1例,差1例.结论 关节镜下...     

关节镜下微骨折治疗距骨骨软骨损伤的临床观察

目的:采用关节镜下清创和微骨折治疗距骨骨软骨损伤,观察其临床效果。方法:收集自2011年1月至2013年12月就诊的42例距骨骨软骨损伤患者,平均年龄35.9岁,其中男28例,女14例,34例有明确受伤史,MRI显示距骨骨软骨损伤≥3级,采用关节镜下清创和微骨折进行治疗。术前、术后1年和术后2年采用美国足踝外科(AOFAS)踝-后足评分系统评估关节功能,术后2年采用MRI检查评估距骨骨软骨恢复情况。结果 :术前MRI诊断3期23例,4期9例,5期10例。按照9宫格分区法,则骨软骨损伤位于4区25例,6区11例,1区4例,3区2例。伴有软骨下骨囊性变8例,均位于4区。采用美国足踝外科(AOFAS)踝-后足评分系统,术后1年73.3±3.9,较术前50.4±7.8明显提高(t=17.018,P=0.00);术后2年81.1±4.8,较术后1年明显提高(t=8.173,P=0.00)。术后2年复查MRI显示骨髓水肿消失。结论:采用关节镜下微骨折治疗距骨骨软骨损伤,可以较好地改善踝关节功能。     

踝关节距骨骨软骨损伤的影像学及关节镜下表现

目的分析踝关节距骨骨软骨损伤的影像学特点,包括病灶位置、病灶大小等形态学数据及MRI分期,并根据关节镜下表现进行分级,分析MRI分期与关节镜分级之间的关系。方法 2006年7月至2008年6月,35例距骨骨软骨损伤患者术前进行踝关节正侧位X线检查及MRI检查,分别根据BerdntHarty标准及Hepple's标准进行分期,在PACS系统上应用测量软件工具分析MRI图像,确定病灶位置、测量其前后径、左右径及深度。所有患病的踝关节均进行关节镜探查,并进行病灶分级。分析MRI分期与关节镜下分级之间的相关性。结果 35例患者的平均年龄为29.1岁(16～44岁),其中男30例,女5例。通过X线发现13例距骨骨软骨损伤,根据BerdntHarty分期:6例为Ⅰ期,3例为Ⅱ期,3例为Ⅲ期,1例为Ⅳ期;6例病灶位于外侧,7例位于内侧。MRI检查共发现38处距骨骨软骨损伤(3例患者均有两处病灶),根据Hepple分期:Ⅰ期1例,Ⅱ期17例,Ⅲ期7例,Ⅳ期2例,Ⅴ期11例。14例病灶位于外侧,24例位于内侧;按照9宫格分区法,55.3%的病灶位于4区(内侧中部),23.7%位于6区(外侧中部)。内侧组病灶大小为:前后径(9.0±2.5)mm、左右径(11.2±2.9)mm、深度(8.4±4.0)mm;外侧组病灶大小为:前后径(7.8±3.2)mm、左右径(10.9±3.2)mm、深度(7.9±4.2)mm。两组病灶大小的差异无统计学意义。关节镜探查共发现38处距骨骨软骨损伤(A级1例、B级1例、C级4例、D级27例、E级3例、F级2例)。MRI分期与关节镜下分级之间无相关性(r=0.12,P=0.474)。结论距骨骨软骨损伤主要位于距骨内侧中部及外侧中部,内侧病损以Hepple's Ⅱ期和Ⅴ期为主,外侧病变以Ⅲ期为主;内外侧病灶的大小差异无统计学意义。内外侧病变的关节镜下表现均以D级为主。Hepple'sMRI影像学分期与关节镜下分级无对应关系。     

关节镜下微骨折技术治疗距骨骨软骨损伤60例疗效观察

目的探讨关节镜下微骨折技术治疗距骨骨软骨损伤的疗效。方法采用关节镜下微骨折技术治疗距骨骨软骨损伤60例,观察踝关节功能评分及疼痛评分变化。结果 60例患者术后踝关节功能评分较术前平均提高20.1分,差异具有统计学意义(P<0.05);术后疼痛评分较术前平均降低5.1分,差异具有统计学意义(P<0.05)。结论关节镜下微骨折技术治疗距骨骨软骨损伤,具有显著的临床疗效,值得推广应用。     

踝关节骨折伴距骨软骨损伤的实验及临床研究

目的：探讨踝关节骨折伴距骨软骨损伤的规律及治疗。方法：通过应用踝关节骨骼标本及距骨模型，观察在模拟踝关节骨折各种外力应用下距骨模型受力及关节面压缩情况，并对42例踝关节骨折在关节镜辅助下手术所见及关节镜图像进行分析。结果：踝部骨折伴距骨软骨损伤的部位、程度与损伤时足位置及外力、关节类型密切相关，有一定的规律可循。结论：此规律有利于踝关节镜入路的选择和手术步骤的制定，遵循其规律可做到踝关节镜手术操作准确，避免漏诊，减少意外损伤，并提高临床治疗效果。     

关节镜下微骨折治疗距骨软骨损伤的临床疗效

目的 探究在踝关节镜下微骨折治疗距骨软骨损伤的临床疗效。方法 回顾性分析自2018年8月至2019年12月西安交通大学附属红会医院足踝外科行踝关节镜下微骨折治疗的20例距骨软骨损伤患者资料,其中男12例,女8例;左足14例,右足6例;年龄18～50岁,平均(28.3±10.8)岁;病程6～12个月,平均(8.3±3.2)个月。在踝关节镜下行清理术,显露距骨损伤部位,给予微骨折处理。采用美国骨科足与踝关节协会(American orthopedic foot and ankle society, AOFAS)踝-后足评分系统和疼痛视觉模拟评分(visual analogue scale, VAS)及影像学进行临床疗效评估。结果 患者均顺利完成手术,手术时间30～40 min。术中未出现血管、神经损伤等严重并发症。患者均获得有效随访,随访时间10～14个月,平均(12.1±1.1)个月。末次随访时AOFAS及VAS较术前均有显著性改善(P<0.05)。末次随访时MRI示距骨软骨损伤范围及程度较术前明显缩小。结论 踝关节镜下微骨折治疗距骨软骨损伤,改善关节功能及疼痛,疗效确切,且术后并...     

踝关节骨折合并距骨软骨损伤的手术治疗

2010年1月～2012年8月,我科共收治踝关节骨折患者36例,术中发现有15例合并距骨软骨损伤,经治疗疗效满意,报道如下。1材料与方法1.1病例资料本组15例,男13例,女2例,年龄25～52岁。踝关节骨折按Lauge-Hansen分类:旋后内收型2例,旋后外旋型6例,旋前外展型3例,旋前外旋型4例。距骨软骨损伤按Berndt-Har-ty分类[1]:Ⅰ型3例,Ⅱ型5例,Ⅲ型3例,Ⅳ型4例。     

距骨骨软骨损伤治疗研究进展

踝关节损伤晚期并发症距骨骨软骨损伤,严重影响踝关节功能.根据病史、临床症状及影像学检查一般可确诊,根据临床分期选择合适的治疗方法是取得良好疗效的前提.对急性期无移位或早期距骨骨软骨损伤患者,可采用石膏固定和避免负重的保守治疗方法延缓病程发展.对不稳定或保守治疗无效患者需采用手术治疗,关节镜技术是目前常用的治疗方法,其创伤小且疗效好;内固定的疗效也较好;对缺损较大的患者,可采用自体或异体骨软骨移植术;自体软骨细胞移植术无缺损面积限制,且无供区损伤.该文就距骨骨软骨损伤的分期、诊断及治疗等的研究进展作一综述.     

关节镜下清创结合微骨折术治疗局灶性距骨软骨损伤

目的探讨关节镜下清创结合微骨折术治疗局灶性距骨软骨损伤的临床疗效。方法对43例局灶性距骨软骨损伤患者进行治疗与随访。应用AOFAS评分和VAS疼痛评分对最终随访结果和术前评分进行对比,并对关节活动度和并发症进行评估。结果术前AOFAS评分为(70.9±3.6)分,术后为(84.3±4.7)分,术后较术前显著提高(P<0.05);VAS疼痛评分术前为(7.6±1.2)分,术后为(2.7±1.6)分,术后较术前显著降低(P<0.05);术后关节活动度正常,无严重并发症出现。结论关节镜下清创结合微骨折技术治疗局灶性距骨软骨损伤短期疗效满意。     

Treatment strategies for osteochondral lesions of the talus: A review of the recent evidence

BackgroundThere has been no consensus regarding the treatment of osteochondral lesions of the talus, there has been many attempts to formulate a treatment pathway, with multiple proposed modalities and adjuncts used.ObjectivesThe aim of this paper was to investigate the evidence published in the recent history, identify the relevant papers, review and summarize the findings, to help clarify the available operative treatment options and their respective efficacies based on the level of evidence provided.Study design & methodsA literature search through electronic databases MEDLINE and EMBASE was done, these databases were screened for publications and papers form June 2004 to June 2019. Key words were utilised in the search ‘talus, talar, tibia, cartilage, osteochondral, ankle, osteochondritis dissecans, articular cartilage’. Studies on adults aged 18–60 years were included. Exclusion criteria were studies with less than 10 patients, or no clear outcome was recorded. Papers were reviewed by the authors and data extracted as per a pre-defined proforma.ResultsFollowing screening, 28 published articles were included and reviewed. Of these publications 5 were level I, 7 level II, 4 level III and 12 level IV. The total number of patients was 1061 patients. Treatment modalities included arthroscopic microfracture, drilling, hyaluronic acid injection, platelet rich plasma, osteochondral autologous transplantation (OAT), vascularised free bone graft among others. The most common functional measures used to assess efficacy were the Visual analogue scale (VAS) and the American Orthopaedic Foot and Ankle (AOFAS) score. Follow up ranged from 26 weeks upto 4 years.ConclusionsDespite the abundance of treatment options, high level evidence (level I) remains limited and does not conclude a definitive treatment modality as superior to others. Further research, in the form highly organised randomised clinical trials, is needed to help improve the efficacy and develop new treatment modalities in the future.     

YouTube provides low-quality videos about talus osteochondral lesions and their arthroscopic treatment

BackgroundMedical professionals and patients commonly use the YouTubeTM platform in their research on health information. The quality of videos about talus osteochondral defect (OCD) and arthroscopic surgery has not been evaluated previously. The aim of this study was to interpret the quality and sufficiency of YouTubeTM videos about talus OCD and arthroscopic surgery.MethodsThe present study is a quality control study of videos on OCD and their arthroscopic treatment. The videos were interpreted in terms of Journal of the American Medical Association (JAMA), DISCERN (Quality Criteria for Consumer Health Information), The Global Quality Score (GQS) and Talus OCD - Specific Score (TOCDSS) by two blinded observers to assess the accuracy of these methods.ResultsInter-observer agreement was "very high" for JAMA, DISCERN, and TOCDSS, while "high" for GQS. There was a statistical relationship and a positive correlation between the scoring systems.ConclusionThe content and quality of YouTubeTM videos about talus OCD and arthroscopic treatment are insufficient.     

One step treatment of talus osteochondral lesions with microfracture and cell free hyaluronic acid based scaffold combination

ObjectiveThe aim of this study was to assess the effectiveness of microfracture and cell free hyaluronic acid (HA) based scaffold combination in the treatment of talus osteochondral defects (OCD).MethodsThis study retrospectively evaluated the clinical results of the 20 patients (14 males and 6 females, mean age at the time of surgery: 32.9 years (range: 16–52 years)) who were treated with MFx and cell-free HA-based scaffold combination for talus OCD smaller than 1.5 cm² and deeper than 7 mm. Results were evaluated with AOFAS and VAS scores. Also, patients' satisfaction was questioned.ResultsPatients were evaluated after an average follow-up of 20.3 months. Intraoperative measurements showed that mean depth of the lesions were 10.4 ± 1.9 mm after debridement. The mean preoperative AOFAS score was 57.45 ± 9.37, which increased to 92.45 ± 8.4 postoperatively (p < 0.05). VAS score was improved from 7.05 ± 2.45 to 1.65 ± 2.20 postoperatively (p < 0.05).ConclusionMFx and cell-free HA-based scaffold combination appear to be a safe and efficient technique that provide good clinical outcomes for lesions deeper than 7 mm.Level of evidenceLevel IV, Therapeutic Study.     

Arthroscopic treatment of ankle osteochondral lesions

Arthroscopic treatment of osteochondral lesions (OCLs) of the ankle is a popular first-line surgical option after conservative therapy has failed. MRI is the preferred imaging modality to evaluate OCLs and aid in surgical planning. Associated soft tissue pathology must be appreciated and addressed surgically, because associated synovitis and soft tissue impingement often contribute to symptoms. The diverse treatment modalities available via arthroscopy offer simplistic and straightforward solutions for biologically and mechanically complicated pathology. Marrow-stimulating techniques, particularly microfracture, have shown good to excellent results in most patients with small (<15 mm) acute lesions, and have a low complication rate.     

Osteochondral autograft transfer (mosaicplasty) for treatment of patients with osteochondral lesions of talus

Purpose:Osteochondral lesion of talus(OLT)is one of the common causes of ankle pain.This disorder is common in young athletes after ankle injury.There are various therapeutic options.One of the options is mosaic plasticizer.The purpose of this study was to investigate the effect of mosaicplasty on improvement of symptoms of patients with osteochondral lesions of talus.Methods:Nineteen patients with osteochondral lesions of talus participated in this study,who were treated with mosaicplasty.Before and after treatment,pain(visual analogue scale),function(American Orthopaedic Foot and Ankle Society),range of motion and radiographic signs were evaluated.Results:The results of this study showed that mosaicplasty could significantly reduce pain,increase function and improve radiographic symptoms.The range of motion increased after treatment,which was not significant.Conclusion:We can confirm the effect of mosaicplasty on the improvement of patients with osteochondral lesions of the ankle,suggesting it as a treatment option.     

No mid-term difference in mosaicplasty in previously treated versus previously untreated patients with osteochondral lesions of the talus

Introduction Osteochondral transplantations, albeit technically challenging, appear promising not only in knee joint lesions, but also in the treatment of talus lesions. We hypothesized that in patients suffering osteochondral lesions of the talus, favorable outcomes are obtained in patients undergoing primary mosaicplasty as compared to patients undergoing secondary mosaicplasty. Materials and methods Over a 3-year period (1998–2001), 14 patients (six male, eight female, median age 22 years) were treated with an autologous osteochondral transplantation of the talus. Eight patients were previously untreated (group I). Six patients had previous ankle procedures, such as microfracturing (group II). The median follow-up was 24 months and 100% complete at 12 months. The functional outcome was evaluated at least at 6 weeks, 12 weeks, and 1 year after surgery using pain on a visual analog scale (VAS) and sports activity was recorded at 1 year after surgery. In ten patients, magnetic resonance imaging (MRI) of the ankle was performed at 1 year after surgery (group I/II: 7/3). Results Overall ankle pain was decreased from 6.9 ± 2.1 to 4.0 ± 2.8 postoperatively. The mean knee pain for the donor knee was 2.6 ± 2.4. We found no significant difference between the primary mosaicplasty group and the secondary mosaicplasty group with regard to pain. MRI scans of ten patients showed a complete incorporation of the osteochondral cylinders at 1 year after surgery. Conclusion Favorable outcomes were obtained in patients undergoing primary mosaicplasty as compared to patients undergoing secondary mosaicplasty. We found no significant difference among patients with previous ankle surgery in contrast to those without, with a median 24-months follow-up.     

Mid-term results after treatment of complex talus osteochondral defects with HemiCAP implantation

BackgroundHemiCAP for complex osteochondral defects (OCDs) in talus has been on the market since 2008. Few follow-up studies exist. Patients with complex OCDs were followed for up to 81 months.Methods31 consecutive patients were assessed preoperatively and at final follow-up, mean 50 months. All patients were treated with the HemiCAP®, Arthrosurface Inc., USA inlay. Inclusion criteria were complex OCDs of the medial or lateral talus dome.ResultsAll outcome measures i.e. AOFAS, FAOS and NRS improved significantly.71.8 % of the cohort were employed preoperatively.At final follow up 87.5% were employed. No revisions of the HemiCAP was performed, but 41,9% had supplementary surgery. 1 patient had a superficial infection otherwise no complications were found. Preoperative and final follow-up x-rays were analysed.ConclusionsMid-term results after HemiCAP talus are good. Patient information and selection is mandatory due to the high numbers of additional surgeries following the HemiCap implantation.     

Outcomes of bone marrow aspirate concentrate and matrix-induced chondrogenesis (BMIC) for treatment of osteochondral lesions of the talus

BackgroundTo analyze the outcomes of Bone marrow aspirate concentrate and Matrix-Induced Chondrogenesis (BMIC) in Osteochondral Lesions of the Talus (OLTs).MethodsPatients with OLTs treated with BMIC from June 2013 to July 2020 were included. Visual Analogue Scale (VAS), Foot Function Index (FFI), and Foot Ankle Outcome Score (FAOS) before treatment and at last follow-up were subjected to analysis.ResultsForty-five patients were included and mean follow-up was 39.1 months (range, 13–97 months). Mean lesion size and depth were 180.7 ± 110.4 mm² and 9.6 ± 3.7 mm, respectively. BMIC was performed without malleolar osteotomy in 36 patients (80%) and bone graft was performed in 42 (93.3%). VAS, FFI, and FAOS improved significantly. No complication occurred and no revision was required.ConclusionsThe BMIC procedure is feasible and should be considered a viable treatment option for OLTs associated with large subchondral bone defects.